Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METO: Obesity, IL-6 and Metabolism
NCT04687540Completed
- Sponsor
- Rigshospitalet
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Single-blind, single-arm trial of tocilizumab, sponsored by Rigshospitalet. Primary endpoints: Whole-body, fat and skeletal muscle fat turnover, Whole-body, fat and skeletal muscle glucose turnover and 2 more. Started Apr 2021; status: completed.
02
Drugs
tocilizumab
Beyond the preview
Go deeper on NCT04687540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687540.